Abstract:Background: There have been several recent advances in the care of patients with chronic kidney disease (CKD), including the use of sodium glucose cotransporter 2 (SGLT2) inhibitors and selective mineralocorticoid receptor antagonists (MRAs). There are very few data reporting the outcomes of these treatments in real-world experience. The aim of this retrospective study is to report the effects of SGLT2 inhibitors, finerenone, and their combination in CKD patients in our community-based setting. Methods: Ninety-eight patients with CKD with an estimated glomerular filtration rate (eGFR) between 25 and 90 mL/min per 1.73 m2 and a urine albumin-to-creatinine ratio (UACR) ≥ 30 mg/g were included. Patients were divided into three groups: two monotherapy groups of SGLT2 inhibitors or finerenone and a third combination group of therapy with SGLT2 inhibitors for the first 4 months and SGLT2 inhibitors and finerenone subsequently. The primary outcomes were the timing and percentage of patients achieving a >50% reduction in UACR from baseline. Results: Group 1 comprised 52 patients on SGLT2i, group 2 had 22 patients on finerenone, and group 3 had 24 patients on combination therapy. The baseline median UACR and mean eGFR were 513 mg/g and 47.9 mL/min per 1.73 m2 in group 1, 548.0 mg/g and 50.5 mL/min per 1.73 m2 in group 2, and 800 mg/g and 60 mL/min per 1.73 m2 in group 3. At baseline, 71 (72.4%) patients were on the angiotensin-converting enzyme inhibitor (ACEi) or the angiotensin receptor blocker (ARB), and 78 (79.5%) patients had type 2 diabetes. After 8 months of follow-up, a >50% decrease in albuminuria was achieved in 96% of patients in group 3, compared to 50% in group 1 and 59% in group 2 (p-values were <0.01 and <0.01, respectively). There was a statistically but not clinically significant change in mean potassium levels in group 2 (+0.4 mmol/L) compared to either group 1 (0.0 mmol/L with p-value: <0.01) or group 3 (−0.01 mmol/L with p-value: <0.01). However, there was no difference in potassium levels when comparing groups 1 and 3. At the end of the follow-up, the average difference in eGFR was −3.4 (8.8), −5.3(10.1), and −7.8 (11.2) mL/min per 1.73 m2 in groups 1, 2, and 3, respectively, without a statistically significant difference between groups. Conclusions: In this real-world experience in our community setting, the combination of SGLT2 inhibitors and finerenone in our adult patients with CKD was associated with a very significant and clinically relevant reduction in UACR, without an increased risk of hyperkalemia. Combination therapy of SGLT2 inhibitor and finerenone regarding background use of ACEi/ARB is feasible and should be encouraged for further albuminuria reductions in CKD patients.

Comparison of the Efficiency of Sulodexide, Ginaton and Valsartan Treatment on Microalburninuria in Patients with Metabolic Syndrome

Influence of valsartan on Microalbuminuria of Essential Hypertensive Patients

Effect of telmisartan on microalbuminuria in patients with hypertension

Clinical efficacy of double dose valsartan on hypertension complicated with microalbuminuria in elderly

Effects of valsartan combined with α-lipoic acid on renal function in patients with diabetic nephropathy: a systematic review and meta-analysis

Comparative Efficacy And Safety Of Antihypertensive Agents For Adult Diabetic Patients With Microalbuminuric Kidney Disease: A Network Meta-Analysis

Efficacy and Safety of Valsartan in Reducing Blood Pressure and Albuminuria in Chinese Patients with Essential Hypertension: a Multicenter Prospective Open-Label Observational Study

Synergistic Effects of Yiqi Huazhuo Gushen Herbal Formula and Valsartan on Metabolic Syndrome Complicated with Microalbuminuria

Effects of short-term glycemic control, low protein diet and administration of enalapril on renal hemodynamics and protein permselectivity in type 2 diabetic patients with microalbuminuria

Evaluation of the Therapeutic Effects of Rosuvastatin Combined with Valsartan in Treating Early Diabetic Nephropathy

Real-Life Experience on the Effect of SGLT2 Inhibitors vs. Finerenone vs. Combination on Albuminuria in Chronic Kidney Disease

Efficacy analysis of valsartan combined with salvia tetramethylpyrazine in the treatment of early diabetic nephropathy

Effect of allopurinol on albuminuria in type 2 diabetic kidney disease with hyperuricemia

Comparison of Clinical Effects of Sacubitril Valsartan Sodium Tablets and Nifedipine Controlled-Release Tablets in the Treatment of Chronic Renal Insufficiency Complicated with Hypertension

The Effects of Sulodexide on Proteinuria in Patients with Diabetic Nephropathy

Efficacy of ursodeoxycholic acid in treatment of early diabetic nephropathy: report of 40 cases

Effect of Simvastatin on the Excretion of Urine Microalbuminuria, TGFβ1, Type Ⅳ Collagen and Laminin in Patients with Diabetic Nephropathy

Combined Therapy of Angiotensin-Converting Enzyme Inhibitor and Angiotensin-ⅱ Receptor Antagonist in Type 2 Diabetic Patients with Overt Albuminuria

The Effect of Losartan on Microalbuminuria in the Treatment of Early Stage of Diabetic Nephropathy Independent of Blood Pressure

Study on Effect of Benazepril and Telmisartan in the Treatment of Patients with Patients with Early Diabetic Nephropathy

EFFECT OF DIFFERENT ANTIHYPERTENSIVE STRATEGIES ON THE MICROALBUMINURIA EXCRETION